Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Investing Activities: 2017-2024

Historic Cash from Investing Activities for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $60.8 million.

  • BridgeBio Pharma's Cash from Investing Activities fell 88.32% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.4 million, marking a year-over-year decrease of 120.91%. This contributed to the annual value of $60.8 million for FY2024, which is 12.49% up from last year.
  • As of FY2024, BridgeBio Pharma's Cash from Investing Activities stood at $60.8 million, which was up 12.49% from $54.0 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Cash from Investing Activities peaked at $453.1 million during FY2022, and registered a low of -$200.8 million during FY2021.
  • Moreover, its 3-year median value for Cash from Investing Activities was $60.8 million (2024), whereas its average is $189.3 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first slumped by 278.97% in 2021, then soared by 325.64% in 2022.
  • BridgeBio Pharma's Cash from Investing Activities (Yearly) stood at -$53.0 million in 2020, then plummeted by 278.97% to -$200.8 million in 2021, then spiked by 325.64% to $453.1 million in 2022, then crashed by 88.08% to $54.0 million in 2023, then climbed by 12.49% to $60.8 million in 2024.